Emergent Biosolutions Inc (NYSE: EBS) Rose 83.2% From Its 52-Week Low; YTD Numbers Rose 252.08% – Here Are Some Things To Keep In Mind

During the last session, Emergent Biosolutions Inc (NYSE:EBS)’s traded shares were 1.55 million, with the beta value of the company hitting 1.59. At the end of the trading day, the stock’s price was $8.45, reflecting an intraday loss of -5.38% or -$0.48. The 52-week high for the EBS share is $15.10, that puts it down -78.7 from that peak though still a striking 83.2% gain since the share price plummeted to a 52-week low of $1.42. The company’s market capitalization is $456.47M, and the average intraday trading volume over the past 10 days was 1.84 million shares, and the average trade volume was 3.02 million shares over the past three months.

Emergent Biosolutions Inc (EBS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.33. EBS has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.14.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Emergent Biosolutions Inc (NYSE:EBS) trade information

Emergent Biosolutions Inc (EBS) registered a -5.38% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.38% in intraday trading to $8.45, hitting a weekly high. The stock’s 5-day price performance is -5.48%, and it has moved by 11.62% in 30 days. Based on these gigs, the overall price performance for the year is 168.25%. The short interest in Emergent Biosolutions Inc (NYSE:EBS) is 8.23 million shares and it means that shorts have 3.12 day(s) to cover.

The consensus price target of analysts on Wall Street is $51.5, which implies an increase of 83.59% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $38 and $65 respectively. As a result, EBS is trading at a discount of -669.23% off the target high and -349.7% off the low.

Emergent Biosolutions Inc (EBS) estimates and forecasts

Statistics show that Emergent Biosolutions Inc has outperformed its competitors in share price, compared to the industry in which it operates. Emergent Biosolutions Inc (EBS) shares have gone up 285.84% during the last six months, with a year-to-date growth rate more than the industry average at 79.13% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 129.20% this quarter and then jump 89.60% in the quarter after that. In the rating firms’ projections, revenue will increase 7.00% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 297.5M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 270.5M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 270.5M and 276.6M respectively. In this case, analysts expect current quarter sales to grow by 10.00% and then drop by -2.20% in the coming quarter.

While earnings are projected to return 71.54% in 2024.

EBS Dividends

Emergent Biosolutions Inc is due to release its next quarterly earnings in November. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Emergent Biosolutions Inc (NYSE:EBS)’s Major holders

Emergent Biosolutions Inc insiders own 2.13% of total outstanding shares while institutional holders control 57.55%, with the float percentage being 58.80%. BLACKROCK INC. is the largest shareholder of the company, while 173.0 institutions own stock in it. As of 2024-06-30, the company held over 3.84 million shares (or 7.3551% of all shares), a total value of $26.18 million in shares.

The next largest institutional holding, with 3.67 million shares, is of VANGUARD GROUP INC’s that is approximately 7.0234% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $25.0 million.